Quest Buys Anatomic Pathology Firm PhenoPath

Sep 27, 2018

|

NEW YORK (360Dx) – Quest Diagnostics announced today it has acquired specialized anatomic pathology service firm PhenoPath.

The deal, whose terms were not disclosed, continued a buying spree for Quest this week, which included the acquisitions of Oxford Immunotec's US lab business and fertility and fertility diagnostics services firm ReproSource.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Quest Buys Anatomic Pathology Firm PhenoPath

To read the full story....

Breaking News

Guardant Health Prices $315M Public Offering

Sienna Cancer Diagnostics, Triolab Ink Distribution Deal for Bladder Cancer Test in Sweden

Ravgen Sues Natera Over Cell-Free DNA Genetic Testing Patents

Agilent to Raise $500M Through Senior Notes Offering

Coca-Cola Bottle Maker, Longhorn Diagnostics Partner on Coronavirus Test Tube Manufacture

MeMed Receives CE-IVD Mark for Infectious Disease Test, POC Platform

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

What's Popular?

AMP SARS-CoV-2 Molecular Dx Survey Shows Supply Chain Issues Hampered Ramp Up of Testing

Quest Diagnostics Receives FDA Emergency Use Authorization for COVID-19 Self-Collection Test Kit

Congress Introduces Bipartisan Bills to Improve Access to SARS-CoV-2 Testing

Sponsorships